Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase

被引:490
|
作者
Mol, CD [1 ]
Dougan, DR
Schneider, TR
Skene, RJ
Kraus, ML
Scheibe, DN
Snell, GP
Zou, H
Sang, BC
Wilson, KP
机构
[1] Syrrx Inc, San Diego, CA 92121 USA
[2] Italian Fdn Canc Res, Inst Mol Oncol, I-20139 Milan, Italy
关键词
D O I
10.1074/jbc.M403319200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The activity of the c-Kit receptor protein-tyrosine kinase is tightly regulated in normal cells, whereas deregulated c-Kit kinase activity is implicated in the pathogenesis of human cancers. The c-Kit juxtamembrane region is known to have an autoinhibitory function; however the precise mechanism by which c-Kit is maintained in an autoinhibited state is not known. We report the 1.9-Angstrom resolution crystal structure of native c-Kit kinase in an autoinhibited conformation and compare it with active c-Kit kinase. Autoinhibited c-Kit is stabilized by the juxtamembrane domain, which inserts into the kinase-active site and disrupts formation of the activated structure. A 1.6-Angstrom crystal structure of c-Kit in complex with STI-571 ( Imatinib(R) or Gleevec(R)) demonstrates that inhibitor binding disrupts this natural mechanism for maintaining c-Kit in an autoinhibited state. Together, these results provide a structural basis for understanding c-Kit kinase autoinhibition and will facilitate the structure-guided design of specific inhibitors that target the activated and autoinhibited conformations of c-Kit kinase.
引用
收藏
页码:31655 / 31663
页数:9
相关论文
共 50 条
  • [1] Effect of STI-571, a c-kit tyrosine kinase inhibitor, in mestastasic gastrointestinal tumor
    Calvo, E
    Fernández, FJ
    Forteza, J
    Brugarolas, A
    MEDICINA CLINICA, 2002, 119 (10): : 396 - 397
  • [2] Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase
    Schindler, T
    Bornmann, W
    Pellicena, P
    Miller, WT
    Clarkson, B
    Kuriyan, J
    SCIENCE, 2000, 289 (5486) : 1938 - 1942
  • [3] Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor
    Heinrich, MC
    Griffith, DJ
    Druker, BJ
    Wait, CL
    Ott, KA
    Zigler, AJ
    BLOOD, 2000, 96 (03) : 925 - 932
  • [4] The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy
    Attoub, S
    Rivat, C
    Rodrigues, S
    Van Bocxlaer, S
    Bedin, M
    Bruyneel, E
    Louvet, C
    Kornprobst, M
    André, T
    Mareel, M
    Mester, J
    Gespach, C
    CANCER RESEARCH, 2002, 62 (17) : 4879 - 4883
  • [5] c-Abl tyrosine kinase and inhibition by the cancer drug imatinib (Gleevec/STI-571)
    Nagar, Bhushan
    JOURNAL OF NUTRITION, 2007, 137 (06): : 1518S - 1523S
  • [6] STI-571: an anticancer protein-tyrosine kinase inhibitor
    Roskoski, R
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2003, 309 (04) : 709 - 717
  • [7] Inhibition of c-Kit by tyrosine kinase inhibitors
    Galanis, Allison
    Levis, Mark
    HAEMATOLOGICA, 2015, 100 (03) : E77 - E79
  • [8] Tyrosine kinase inhibitor STI-571 - The new wonder drug of cancer therapy
    Haydon, RC
    Zhou, L
    He, TC
    CANCER BIOLOGY & THERAPY, 2004, 3 (04) : 393 - 394
  • [9] Structural basis for the autoinhibition of c-Abl tyrosine kinase
    Nagar, B
    Hantschel, O
    Young, MA
    Scheffzek, K
    Veach, D
    Bornmann, V
    Clarkson, B
    Superti-Furga, G
    Kuriyan, J
    CELL, 2003, 112 (06) : 859 - 871
  • [10] Structural insights into the conformational selectivity of STI-571 and related kinase inhibitors
    Mol, CD
    Fabbro, D
    Hosfield, DJ
    CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT, 2004, 7 (05) : 639 - 648